NASDAQ:CLLS - Cellectis Stock Price, Forecast & News

Cellectis trades on the NASDAQ under the ticker symbol "CLLS."

Cellectis SA (NASDAQ:CLLS) announced its quarterly earnings results on Tuesday, August, 6th. The biotechnology company reported ($0.79) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.61) by $0.18. The biotechnology company earned $2.93 million during the quarter, compared to analyst estimates of $3.45 million. View Cellectis' Earnings History.

Cellectis is scheduled to release their next quarterly earnings announcement on Monday, March 9th 2020. View Earnings Estimates for Cellectis.

6 Wall Street analysts have issued 12-month target prices for Cellectis' shares. Their forecasts range from $20.00 to $73.00. On average, they expect Cellectis' stock price to reach $40.40 in the next twelve months. This suggests a possible upside of 131.3% from the stock's current price. View Analyst Price Targets for Cellectis.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cellectis in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Cellectis.

News coverage about CLLS stock has trended somewhat positive recently, according to InfoTrie Sentiment Analysis. The research group identifies positive and negative media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Cellectis earned a coverage optimism score of 2.0 on InfoTrie's scale. They also assigned headlines about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the next several days. View News Stories for Cellectis.

Cellectis saw a drop in short interest in January. As of January 31st, there was short interest totalling 226,800 shares, a drop of 7.5% from the January 15th total of 245,100 shares. Based on an average daily trading volume, of 134,600 shares, the short-interest ratio is currently 1.7 days. Approximately 0.5% of the company's stock are short sold. View Cellectis' Current Options Chain.

Based on aggregate information from My MarketBeat watchlists, some companies that other Cellectis investors own include Calyxt (CLXT), NVIDIA (NVDA), Gilead Sciences (GILD), Advanced Micro Devices (AMD), Exelixis (EXEL), Editas Medicine (EDIT), Micron Technology (MU), Alibaba Group (BABA), WEC Energy Group (WEC) and Neurocrine Biosciences (NBIX).

(CLLS) raised $129 million in an initial public offering on Wednesday, March 25th 2015. The company issued 3,500,000 shares at a price of $36.83 per share. BofA Merrill Lynch, Jefferies and Piper Jaffray acted as the underwriters for the IPO and Oppenheimer was co-manager.

Cellectis' stock is owned by many different of retail and institutional investors. Top institutional investors include FMR LLC (7.50%), ARK Investment Management LLC (3.16%), Nikko Asset Management Americas Inc. (3.01%), Sumitomo Mitsui Trust Holdings Inc. (3.01%), Credit Suisse AG (1.09%) and Rhenman & Partners Asset Management AB (0.34%).

CLLS stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Point72 Asset Management L.P., Sumitomo Mitsui Trust Holdings Inc., Nikko Asset Management Americas Inc., UBS Group AG, Cubist Systematic Strategies LLC, Victory Capital Management Inc. and Eqis Capital Management Inc..

CLLS stock was bought by a variety of institutional investors in the last quarter, including Rhenman & Partners Asset Management AB, ARK Investment Management LLC, Capital Asset Advisory Services LLC, Atria Investments LLC, OneAscent Financial Services LLC, Granite Point Capital Management L.P., Envestnet Asset Management Inc. and Vident Investment Advisory LLC.

Shares of CLLS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of CLLS stock can currently be purchased for approximately $17.47.